Hayley Virgil | Authors

Sugemalimab Study Meets Primary End Point for Refractory Extranodal Natural Killer/T-Cell Lymphoma, Moves Forward With NMPA of China

January 19, 2022

Sugemalimab showed promise in the phase 2 GEMSTONE-201 trial in a group of patients with extranodal natural killer/T-cell lymphoma; developer CStone is set to submit a new drug application for the treatment to the National Medical Products Administration of China.

Meta-Analysis Indicates Black Individuals With Prostate Cancer May Have Better Outcomes in Radiation Therapy Clinical Trials vs White Patients

January 14, 2022

Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.